A Phase 2 Study of Atengenal (A-10) and Astugenal (AS2-1) in Diffuse, Intrinsic Pontine Glioma (DIPG)

Trial Profile

A Phase 2 Study of Atengenal (A-10) and Astugenal (AS2-1) in Diffuse, Intrinsic Pontine Glioma (DIPG)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Antineoplaston A10/antineoplaston AS2-1 (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Acronyms DIPG
  • Sponsors Burzynski Research Institute
  • Most Recent Events

    • 10 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 14 Apr 2016 Status changed from planning to recruiting, as per Burzynski Research Institute media release.
    • 30 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top